Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3478 - Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer

Date

10 Oct 2016

Session

Poster display

Presenters

Angelos Koutras

Citation

Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363

Authors

A. Koutras1, V. Kotoula1, G. Kouvatseas2, C. Christodoulou1, D. Pectasides1, A. Batistatou1, M. Bobos1, E. Tsolaki1, K. Papadopoulou1, G. Pentheroudakis1, P. Papakostas1, S. Pervana1, K. Petraki1, S. Chrisafi1, E. Razis1, A. Psyrri1, D. Bafaloukos1, K.T. Kalogeras1, H.P. Kalofonos1, G. Fountzilas1

Author affiliations

  • 1 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 2 Biostatistics, Health Data Specialists Ltd, Athens/GR
More

Resources

Abstract 3478

Background

In the current study, we performed a complete analysis of gene amplification, copy-number variations (CNV), transcriptional profiling and protein expression of all four HER family receptors, in a series of patients with metastatic breast cancer (MBC), treated with trastuzumab-based regimens. In addition, our analysis included the evaluation of several other factors, such as PTEN and mTOR protein expression by immunohistochemistry (IHC) and PIK3CA mutations.

Methods

Formalin-fixed paraffin-embedded tumor tissue samples were collected from 229 patients, considered to be HER2-positive when assessed at the local laboratories. Central review of HER2 status by fluorescence in situ hybridization and/or IHC revealed that of the 229 patients, only 139 (61%) were truly HER2-positive.

Results

In the multivariate analysis, HER3 gene amplification (using the 75th percentile as a cut-off point) (HR = 0.50, 95% CI 0.27-0.93, p = 0.027), HER3 mRNA expression (75th percentile as a cut-off point) (HR = 0.47, 95% CI 0.22-1.01, p = 0.052) and PTEN protein expression (HR = 0.60, 95% CI 0.37-0.98, p = 0.042) retained their favorable prognostic significance for OS in the HER2-positive subgroup. In HER2-negative patients, none of the significant factors that were identified in the univariate analysis retained prognostic ability for OS. Moreover, wild-type PIK3CA was found to be an independent favorable prognostic factor for TTP in the HER2-positive patients (HR = 0.53, 95% CI 0.27-1.02, p = 0.059). In addition, EGFR CNVs (HR = 4.89, 95% CI 1.23-19.36, p = 0.024), HER3 gene amplification (using the median value as a cut-off point) (HR = 0.41, 95% CI 0.16-1.06, p = 0.067), HER3 protein expression (HR = 0.15, 95% CI 0.04-0.52, p = 0.003) and mTOR protein expression (HR = 0.33, 95% CI 0.13-0.84, p = 0.02) independently affected TTP in the HER2-negative subgroup.

Conclusions

The present study suggests that EGFR is a negative, whereas HER3 is a positive prognostic factor in patients with MBC. Since the above associations were not restricted to HER2-positive patients only, a definitive predictive value for trastuzumab treatment is not documented. Given the retrospective nature of the current analysis, our findings should be considered as hypothesis generating.

Clinical trial identification

N/A

Legal entity responsible for the study

Hellenic Cooperative Oncology Group

Funding

Roche Hellas S.A.

Disclosure

G. Fountzilas: Advisory Board: Roche Hellas S.A. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings